Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients will meet DSM-IV criteria for Bipolar II Disorder, with at least one hypomanic episode as documented in the medical history or provided by an informant, or have evidence of a clear diagnosis of hypomania~* patients will currently be experiencing a major depressive episode of 2 or more weeks, but less than 12 months duration~* minimum score of 18 on the 17-item HAM-D at screen and baseline~Exclusion Criteria:~* patients will not meet criteria for Bipolar I or Schizoaffective Disorder or Schizophrenia~* patients may have co-morbid anxiety or other Axis I disorders as long as depression dominates the clinical picture~* Suicidal ideation or history that makes participation in a clinical trial unduly risky~* unstable medical conditions or any abnormality in thyroid function~* patients with a QTc of 450msec or greater on the initial ECG~* patients requiring concomitant psychotropic drugs will not be eligible, although patients on such drugs who can undergo washout will be eligible. such patients must have discontinued psychoactive drugs at least 2 weeks before beginning study, with 4 weeks for fluoxetine and depot neuroleptics~* the use of Zolpidem 5-10 mg as needed will be permitted for patients suffering from insomnia, but cannot be taken the night before a scheduled assessment~* patients with dementia or substance abuse in the last 6 months~* pregnant or lactating women will be excluded, as will those not using adequate forms of contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ziprasidone (Type: EXPERIMENTAL): Ziprasidone monotherapy, 20-60 mg BID.

Based on this trial design, predict the completion outcome and termination type (if applicable).